LNP Collaborations & Partners

Our Partners


Genevant Sciences, Inc.

Arbutus has granted broad rights to Genevant (a company jointly owned by Arbutus and Roivant Sciences) to use Arbutus’ LNP technology.  Genevant aims to advance multiple product candidates into the clinic across RNAi, mRNA, and gene editing modalities using the Arbutus LNP and ligand conjugate delivery platforms. 

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY)

Arbutus granted a license to Alnylam to use Arbutus' LNP technology to enable RNAi therapeutic products.  Alnylam’s new drug application (NDA) for ONPATTRO™ (patisiran), an RNAi therapeutic, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of hereditary ATTR amyloidosis with polyneuropathy polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Arbutus receives royalty payments on commercial sales of ONPATTRO.  

Acrotech Biopharma, LLC

Marqibo®, originally developed by us, is a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug Vincristine. Marqibo’s approved indication is for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-ALL) in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy. We originally out-licensed Marqibo to Talon Therapeutics Inc. (“Talon”) in 2006, and in July 2013, Talon was acquired by Spectrum Pharmaceuticals, Inc. (“Spectrum”). Spectrum initiated the commercial launch of Marqibo in September 2013 through its existing hematology sales force in the United States. In January 2019, Acrotech Biopharma, LLC, a subsidiary of Aurobindo Pharma USA, Inc., acquired the license for Marqibo from Spectrum. We receive mid-single-digit royalty payments based on Marqibo’s commercial sales. In addition, Marqibo is in ongoing clinical trials evaluating two additional indications, which are Pediatric acute lymphoblastic leukemia and Non-Hodgkin’s lymphoma.

Gritstone Oncology

Gritstone Oncology was granted worldwide access to Arbutus’ portfolio of proprietary and clinically validated lipid nanoparticle (LNP) products and associated intellectual property to deliver Gritstone’s RNA-based neoantigen immunotherapy products. Gritstone will pay Arbutus an upfront payment, payments for achievement of development, regulatory, and commercial milestones, royalties, and will reimburse Arbutus for conducting technology development and providing manufacturing and regulatory support for Gritstone’s product candidates.